Response Genetics' Q1 Revenues Increase 59 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Increased use of its ResponseDx genetic tests drove up Response Genetics' first-quarter revenues 59 percent year over year, the company said today.

The Los Angeles-based cancer molecular diagnostic test developer said that for the three months ended March 31, revenues increased to $5.9 million from $3.7 million, in part due to an 82 percent increase in revenues associated with its ResponseDx tests for colon, lung, and gastric cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.